Clinical and molecular complexity of breast cancer metastases

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 85-95

  Kimbung, Siker ^a   Loman, Niklas ^a,b   Hedenfalk, Ingrid ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Metastasis; Organ specific tropism; Prognosis; Targeted therapy; Tumor heterogeneity

Indexed keywords

BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; DISEASE ASSOCIATION; EARLY CANCER; EPIGENETICS; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; NONHUMAN; PRIMARY TUMOR; REVIEW; SURVIVAL TIME; TROPISM; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BREAST NEOPLASMS; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

TUMOR MARKER;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGAN SPECIFICITY; PROGNOSIS;

EID: 84948714131     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.009     Document Type: Review

References (164)

1. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
2. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
3. American Cancer Society. Global cancer facts and figures 2008. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf.
4. Early Breast Cancer Trialists' Collaborative G, Peto R., Davies C., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
5. IARC GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 2014.
6. Paget S. The distribution of secondary growths in cancer of the breast 1889. Cancer Metastasis Rev. 1989, 8:98-101.
7. Luzzi K.J., MacDonald I.C., Schmidt E.E., et al. Multistep nature of metastatic inefficiency - dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 1998, 153:865-873.
8. Kienast Y., von Baumgarten L., Fuhrmann M., et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16:116-122.
9. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
10. Vanharanta S., Massague J. Origins of metastatic traits. Cancer Cell 2013, 24:410-421.
11. Fidler I.J. Selection of successive tumour lines for metastasis. Nat. N. Biol. 1973, 242:148-149.
12. Fidler I.J. Critical determinants of metastasis. Semin Cancer Biol. 2002, 12:89-96.
13. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805:105-117.
14. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
15. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
16. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
17. Wan L., Pantel K., Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 2013, 19:1450-1464.
18. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70:5649-5669.
19. Koscielny S., Tubiana M., Le M.G., et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br. J. Cancer 1984, 49:709-715.
20. Weigelt B., Glas A.M., Wessels L.F., et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15901-15905.
21. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33:49-54.
22. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
23. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
24. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
25. Husemann Y., Geigl J.B., Schubert F., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
26. Fisher B., Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J. Natl. Cancer Inst. Monogr. 1992, 105-116.
27. Vecchi M., Confalonieri S., Nuciforo P., et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008, 27:2148-2158.
28. Torres L., Ribeiro F.R., Pandis N., et al. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res. Treat. 2007, 102:143-155.
29. Schmidt-Kittler O., Ragg T., Daskalakis A., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7737-7742.
30. Falck A.K., Bendahl P.O., Chebil G., et al. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res. Treat. 2013, 140:93-104.
31. Criscitiello C., Andre F., Thompson A.M., et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res. 2014, 16.
32. Goldhirsch A., Wood W.C., Coates A.S., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011, 22:1736-1747.
33. Amir E., Clemons M., Purdie C.A., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat. Rev. 2012, 38:708-714.
34. Karlsson E., Appelgren J., Solterbeck A., et al. Breast cancer during follow-up and progression - a population based cohort on new cancers and changed biology. Cancer 2014, 50:2916-2924.
35. Liedtke C., Broglio K., Moulder S., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 2009, 20:1953-1958.
36. Lindstrom L.S., Karlsson E., Wilking U.M., et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J. Clin. Oncol. 2012, 30:2601-2608.
37. Kimbung S., Kovacs A., Danielsson A., et al. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget 2015, [Epub ahead of print].
38. Zhang L., Riethdorf S., Wu G., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18:5701-5710.
39. Bidard F.C., Peeters D.J., Fehm T., et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014, 15:406-414.
40. Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368:1199-1209.
41. Gundem G., Van Loo P., Kremeyer B., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520:353-357.
42. McFadden D.G., Papagiannakopoulos T., Taylor-Weiner A., et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014, 156:1298-1311.
43. Cleary A.S., Leonard T.L., Gestl S.A., Gunther E.J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014, 508:113-117.
44. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8:341-352.
45. Kang Y., Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013, 23:573-581.
46. Bos P.D., Zhang X.H., Nadal C., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
47. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
48. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
49. Oskarsson T., Batlle E., Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14:306-321.
50. Kang Y., Siegel P.M., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
51. Tabaries S., Dong Z., Annis M.G., et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011, 30:1318-1328.
52. Lu X., Mu E., Wei Y., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011, 20:701-714.
53. Jin L., Zhang Y., Li H., et al. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis. Cell Res. 2012, 22:1356-1373.
54. Morales M., Arenas E.J., Urosevic J., et al. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol. Med. 2014, 6:865-881.
55. Ohtaki T., Shintani Y., Honda S., et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001, 411:613-617.
56. Tarin D., Price J.E., Kettlewell M.G.W., et al. Mechanisms of human-tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984, 44:3584-3592.
57. Disibio G., French S.W. Metastatic patterns of cancers: results from a large autopsy study. Arch. Pathol. Lab. Med. 2008, 132:931-939.
58. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68:3108-3114.
59. Soni A., Ren Z., Hameed O., et al. Breast cancer subtypes predispose the site of distant metastases. Am. J. Clin. Pathol. 2015, 143:471-478.
60. Largillier R., Ferrero J.M., Doyen J., et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann. Oncol. 2008, 19:2012-2019.
61. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
62. Kimbung S., Kovacs A., Bendahl P.O., et al. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol. Oncol. 2014, 8:119-128.
63. Yardley D.A. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin. Breast Cancer 2010, 10:64-73.
64. Imkampe A., Bendall S., Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur. J. Surg. Oncol. 2007, 33:420-423.
65. Hess K.R., Varadhachary G.R., Taylor S.H., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
66. Aversa C., Rossi V., Geuna E., et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014, 23:623-628.
67. Davila D., Antoniou A., Chaudhry M.A. Evaluation of osseous metastasis in bone scintigraphy. Semin. Nucl. Med. 2015, 45:3-15.
68. Krzeszinski J.Y., Wan Y. New therapeutic targets for cancer bone metastasis. Trends Pharmacol. Sci. 2015.
69. Hirbe A.C., Morgan E.A., Weilbaecher K.N. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr. Pharm. Des. 2010, 16:1284-1290.
70. Yin J.J., Selander K., Chirgwin J.M., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999, 103:197-206.
71. Zhang X.H., Wang Q., Gerald W., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
72. Zhang X.H., Jin X., Malladi S., et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 2013, 154:1060-1070.
73. Lu X., Wang Q.Q., Hu G.H., et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009, 23:1882-1890.
74. Sethi N., Dai X.D., Winter C.G., Kang Y.B. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
75. Park B.K., Zhang H., Zeng Q., et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 2007, 13:62-69.
76. Zhao Y., Bachelier R., Treilleux I., et al. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007, 67:5821-5830.
77. Sloan E.K., Pouliot N., Stanley K.L., et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8:R20.
78. Lu X., Mu E., Wei Y., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha 4 beta 1-positive osteoclast progenitors. Cancer Cell 2011, 20:701-714.
79. Tamura D., Hiraga T., Myoui A., et al. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int. J. Oncol. 2008, 33:17-24.
80. Siclari V.A., Mohammad K.S., Tompkins D.R., et al. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Res. 2014, 16:458.
81. Cox T.R., Rumney R.M., Schoof E.M., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015, 522:106-110.
82. Wang H., Yu C., Gao X., et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 2015, 27:193-210.
83. Ell B., Mercatali L., Ibrahim T., et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 2013, 24:542-556.
84. Krzeszinski J.Y., Wei W., Huynh H., et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 2014, 512:431-435.
85. Chen Q., Zhang X.H., Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011, 20:538-549.
86. Gupta G.P., Nguyen D.X., Chiang A.C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
87. Padua D., Zhang X.H.F., Wang Q.Q., et al. TGF beta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
88. Oskarsson T., Acharyya S., Zhang X.H., et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
89. Malanchi I., Santamaria-Martinez A., Susanto E., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-95.
90. Gupta G.P., Perk J., Acharyya S., et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19506-19510.
91. Brown D.M., Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004, 5:365-374.
92. Bendell J.C., Domchek S.M., Burstein H.J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2980.
93. Burstein H.J., Lieberman G., Slamon D.J., et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 2005, 16:1772-1780.
94. Sevenich L., Bowman R.L., Mason S.D., et al. Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell. Biol. 2014, 16:876-888.
95. Kodack D.P., Askoxylakis V., Ferraro G.B., et al. Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 2015, 27:163-175.
96. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
97. Valiente M., Obenauf A.C., Jin X., et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014, 156:1002-1010.
98. Tabaries S., Ouellet V., Hsu B.E., et al. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 2015, 17:45.
99. Tabaries S., Dupuy F., Dong Z., et al. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol. Cell. Biol. 2012, 32:2979-2980.
100. Tabaries S., Annis M.G., Hsu B.E., et al. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget 2015, 6:9476-9480.
101. Ma R., Feng Y., Lin S., et al. Mechanisms involved in breast cancer liver metastasis. J. Transl. Med. 2015, 13:64.
102. Kollias J., Elston C.W., Ellis I.O., et al. Early-onset breast cancer - histopathological prognostic considerations. Br. J. Cancer 1997, 75:1318-1320.
103. Albain K.S., Allred D.C., Clark G.M. Breast cancer outcome and predictors of outcome: are there age differentials?. J. Natl. Cancer Inst. Monogr. 1994, 35-42.
104. Chiang A.C., Massague J. Molecular basis of metastasis. N. Engl. J. Med. 2008, 359:2814-2820.
105. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
106. Rosen P.P., Groshen S., Kinne D.W., Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J. Clin. Oncol. 1993, 11:2090-2100.
107. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 2002, 20:3628-3630.
108. Elston C.W., Ellis I.O. Pathological prognostic factors in breast-cancer. 1. The value of histological grade in breast-cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
109. Early Breast Cancer Trialists' Collaborative, Darby G., McGale S.P., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised, trials. Lancet 2011, 378:1707-1710.
110. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009, 20:1319-1329.
111. Early Breast Cancer Trialists' Collaborative, G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised, trials. Lancet 2005, 365:1687-1690.
112. Iwamoto T., Booser D., Valero V., et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J. Clin. Oncol. 2012, 30:729-734.
113. Viale G., Regan M.M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 2007, 25:3846-3850.
114. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1660.
115. Dowsett M., Nielsen T.O., A'Hern R., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 2011, 103:1656-1660.
116. Dressler L.G., Berry D.A., Broadwater G., et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J. Clin. Oncol. 2005, 23:4287-4290.
117. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
118. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
119. Cheang M.C.U., Chia S.K., Voduc D., et al. Ki67 index HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 2009, 101:736-750.
120. Stuart-Harris R., Caldas C., Pinder S.E., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334.
121. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4430.
122. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J. Am. Med. Assoc. 2006, 295:2492-2500.
123. Harbeck N., Sotlar K., Wuerstlein R., Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat. Rev. 2014, 40:434-444.
124. Davies C., Pan H.C., Godwin J., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816.
125. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTG MA.17. J. Natl. Cancer Inst. 2005, 97:1262-1270.
126. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J. Clin. Oncol. 2008, 26:1965-1970.
127. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl. Cancer Inst. 2007, 99:1845-1850.
128. Filipits M., Nielsen T.O., Rudas M., et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin. Cancer Res. 2014, 20:1298-1300.
129. Sestak I., Dowsett M., Zabaglo L., et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 2013, 105:1504-1510.
130. Dubsky P., Brase J.C., Jakesz R., et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br. J. Cancer 2013, 109:2959-2960.
131. Sgroi D.C., Sestak I., Cuzick J., et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013, 14:1067-1070.
132. Drukker C.A., van Tinteren H., Schmidt M.K., et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res. Treat. 2014, 143:587-592.
133. Tevaarwerk A.J., Gray R.J., Schneider B.P., et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 2013, 119:1140-1150.
134. Minn A.J., Kang Y., Serganova I., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 2005, 115:44-55.
135. Wolf D.M., Lenburg M.E., Yau C., et al. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLOS ONE 2014, 9:e98830.
136. Curtis C., Shah S.P., Chin S.F., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
137. Ali H.R., Rueda O.M., Chin S.F., et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 2014, 15:431.
138. Metzger-Filho O., Tutt A., de Azambuja E., et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 2012, 30:1879-1880.
139. Aurilio G., Monfardini L., Rizzo S., et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013, 52:1649-1650.
140. de Duenas E.M., Hernandez A.L., Zotano A.G., et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res. Treat. 2014, 143:507-515.
141. Amir E., Miller N., Geddie W., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012, 30:587-592.
142. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann. Oncol. 2009, 20:1499-1500.
143. Thompson A.M., Jordan L.B., Quinlan P., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010, 12:R92.
144. Cardoso F., Harbeck N., Fallowfield L., et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(SUPPL. 7):vii11-vii19.
145. Forshew T., Murtaza M., Parkinson C., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012, 4:136ra168.
146. Rothe F., Laes J.F., Lambrechts D., et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann. Oncol. 2014, 25:1959-1960.
147. Lin N.U., Thomssen C., Cardoso F., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22:203-210.
148. Pagani O., Senkus E., Wood W., et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J. Natl. Cancer Inst. 2010, 102:456-463.
149. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer. Ann. Oncol. 2007, 18:215-225.
150. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol. 2008, 26:4883-4890.
151. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2010, 28:1124-1130.
152. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
153. Yardley D.A., Noguchi S., Pritchard K.I., et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv. Ther. 2013, 30:870-884.
154. Bendell J.C., Rodon J., Burris H.A., et al. Phase I dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30:282-290.
155. Papadopoulos K.P., Tabernero J., Markman B., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2014, 20:2445-2456.
156. Murphy C.G., Dickler M.N. The role of CDK4/6 inhibition in breast cancer. Oncologist 2015, 20:483-490.
157. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2670.
158. Miles D.W., Dieras V., Cortes J., et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann. Oncol. 2013, 24:2773-2780.
159. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
160. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
161. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
162. Gnant M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat Rev. 2014, 40:476-484.
163. Early Breast Cancer Trialists' Collaborative, G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised, trials. Lancet 2015.
164. Gnant M., Pfeiler G., Dubsky P.C., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015.